Literature DB >> 16908335

Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.

Linda Brubaker1, Christopher Chapple, Karin S Coyne, Zoe Kopp.   

Abstract

Overactive bladder (OAB) is a condition defined by its symptoms--urinary urgency with or without urgency urinary incontinence and often with frequency and nocturia. As such, determining the efficacy of OAB treatments using objective measures, such as urodynamic testing, can be difficult. A better means of gauging treatment efficacy for symptom-based conditions is through the use of patient-reported outcomes (PROs). With PROs, clinicians can gain insight into how a treatment affects a patient's symptoms and whether improvement in symptoms has a positive effect from the patient's perspective. PROs are increasingly being included as end points in clinical trials, including those of antimuscarinic drugs for OAB. Consequently, clinicians should become familiar with the most commonly used instruments. We provide an overview of instruments used to assess symptoms, health-related quality of life, and treatment satisfaction in patients with OAB and discuss how PROs can be incorporated into clinical trial protocols.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908335     DOI: 10.1016/j.urology.2006.05.045

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  21 in total

1.  Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.

Authors:  Yuan Chi Shen; Hung Jen Wang; Yao Chi Chuang
Journal:  Int Urol Nephrol       Date:  2018-06-07       Impact factor: 2.370

Review 2.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

3.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

4.  The psychometric validation of a 1-week recall period for the OAB-q.

Authors:  Karin S Coyne; Heather Gelhorn; Christine Thompson; Zoe S Kopp; Zhonghong Guan
Journal:  Int Urogynecol J       Date:  2011-07-08       Impact factor: 2.894

5.  Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire.

Authors:  Linda Brubaker; Vik Khullar; Elisabeth Piault; Christopher J Evans; Tamara Bavendam; James Beach; Yating Yeh; Zoe S Kopp; Con J Kelleher; Jeffrey Trocio
Journal:  Int Urogynecol J       Date:  2011-03-04       Impact factor: 2.894

6.  Patient and surgeon goal achievement 10 years following surgery for pelvic organ prolapse and urinary incontinence.

Authors:  Sushma Srikrishna; Dudley Robinson; Linda Cardozo; Ganesh Thiagamoorthy
Journal:  Int Urogynecol J       Date:  2015-06-20       Impact factor: 2.894

7.  A clinical perspective on electronically collecting patient-reported outcomes at the point-of-care for overactive bladder.

Authors:  Darren Desantis; Richard J Baverstock; Andrea Civitarese; R Trafford Crump; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

8.  A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms.

Authors:  Lisa C Welch; Elizabeth M Botelho; Jean Journel Joseph; Sharon L Tennstedt
Journal:  Nurs Res       Date:  2012 Jul-Aug       Impact factor: 2.381

9.  Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.

Authors:  N Zinner; K C Kobashi; U Ebinger; A Viegas; M Egermark; E Quebe-Fehling; P Koochaki
Journal:  Int J Clin Pract       Date:  2008-09-22       Impact factor: 2.503

10.  Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

Authors:  D R Staskin; M T Rosenberg; N V Dahl; P V Polishuk; N R Zinner
Journal:  Int J Clin Pract       Date:  2007-11-15       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.